# RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations

> **NCT06185400** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 108 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer
- ERBB2 Mutation-Related Tumors
- ERBB2 Gene Duplication
- Disitamab Vedotin

## Interventions

- **DRUG:** Disitamab Vedotin
- **DRUG:** third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib)
- **DRUG:** pyrotinib

## Key facts

- **NCT ID:** NCT06185400
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-02-01
- **Primary completion:** 2025-07-01
- **Final completion:** 2026-12-01
- **Target enrollment:** 108 (ESTIMATED)
- **Last updated:** 2023-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06185400

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06185400, "RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations". Retrieved via AI Analytics 2026-08-24 from https://api.ai-analytics.org/clinical/NCT06185400. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*